CD19-7×19 CAR-T + PD1 monoclonal antibody

CD19-7×19 CAR-T + PD1 monoclonal antibody is a combination therapy that pairs CD19-targeted chimeric antigen receptor T-cell therapy with a PD1 checkpoint inhibitor. The CD19 CAR-T component is engineered to target CD19-expressing B cells, including malignant B cells in lymphomas and leukemias. The therapy works by genetically modifying a patient's own T cells to express a receptor that recognizes CD19, enabling them to identify and kill CD19-positive cancer cells. The addition of a PD1 monoclonal antibody likely aims to enhance the efficacy of the CAR-T cells by blocking the PD1 immune checkpoint, potentially preventing T-cell exhaustion and improving persistence.